+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06859762

Evaluating the Safety and Effects of YL217 in Adults With Advanced Solid Tumors in a First Human Study

Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2026-09-18

630

Participants Needed

21

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating YL217, an antibody-drug conjugate targeting the CDH17 protein, in patients with advanced solid tumors. This first-in-human Phase 1 study aims to assess the safety, tolerability, pharmacokinetics, and effectiveness of YL217. The study focuses on gastrointestinal cancers, addressing a significant unmet medical need by building on preclinical results that showed tumor growth suppression in animal models. Participants will receive YL217 either alone or in combination with bevacizumab, with or without 5-fluorouracil and leucovorin. YL217 is given through intravenous infusion, and bevacizumab and 5-FULV are also administered via intravenous infusion on a biweekly schedule. The study follows a sequential design with dose escalation, backfill, and expansion phases for both combination and monotherapy groups. During the study, participants will undergo regular monitoring for side effects and dose-limiting toxicities over approximately three years. Assessments include measuring tumor response, pharmacokinetics, immunogenicity, and performance status. Safety evaluations involve tracking adverse events, oxygen saturation, and other clinical parameters. This comprehensive approach will help researchers understand how YL217 behaves in the body and its potential impact on advanced solid tumors.

CONDITIONS

Brief Title

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Research Team

A

Angie Cao, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here